Evidence map›Paper›PMID 26038193›Full record

ArticleCancer2015

Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma.

Franz O Smith, Binglin Yue, Suroosh S Marzban, Brooke L Walls, Michael Carr, Ryan S Jackson, Christopher A Puleo, Tapan Padhya, C Wayne Cruse, Ricardo J Gonzalez and 6 more

Abstract read
In one paragraph

Article in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018
    Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Patterns of Metastasis in Merkel Cell Carcinoma.Annals of surgical oncology · 2021
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Franz O SmithDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Binglin YueDepartment of Biostatistics, Moffitt Cancer Center, Tampa, Florida.
Suroosh S MarzbanMorsani College of Medicine, University of South Florida, Tampa, Florida.
Brooke L WallsDepartment of Dermatology, Brigham and Women's Hospital, Brookline, Massachusetts.
Michael CarrMorsani College of Medicine, University of South Florida, Tampa, Florida.
Ryan S JacksonDepartment of Otolaryngology-Head and Neck Surgery, University of South Florida, Tampa, Florida.
Christopher A PuleoDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Tapan PadhyaDepartment of Otolaryngology-Head and Neck Surgery, University of South Florida, Tampa, Florida.
C Wayne CruseDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Ricardo J GonzalezDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Amod A SarnaikDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Michael J SchellDepartment of Biostatistics, Moffitt Cancer Center, Tampa, Florida.
Ronald C DeContiDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Jane L MessinaDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Vernon K SondakDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Jonathan S ZagerDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.

Funding

Co-Stimulation to Enhance Adoptive Cell Therapy for Metastatic MelanomaK23CA178083 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SARNAIK, AMOD · 2013 to 2017
$826k
NCI NIH HHS K23 CA178083
6 · The paper itself

Abstract

backgroundThe purposes of this study were 1) to determine the impact of primary tumor-related factors on the prediction of the sentinel lymph node (SLN) status and 2) to identify clinical and pathologic factors associated with survival in Merkel cell carcinoma (MCC).

methodsAn institutional review board-approved, retrospective review of patients with MCC treated between 1988 and 2011 at a single center was performed. Patients were categorized into 5 groups: 1) negative SLN, 2) positive SLN, 3) clinically node-negative but SLN biopsy not performed, 4) regional nodal disease without a known primary tumor, and 5) primary MCC with synchronous clinically evident regional nodal disease. Factors predictive of the SLN status were analyzed with logistic regressions, and overall survival (OS) and disease-specific survival (DSS) were analyzed with Cox models and competing risk models assuming proportional hazards, respectively.

resultsThree hundred seventy-five patients were analyzed, and 70% were male; the median age was 75 years. The median tumor diameter was 1.5 cm (range, 0.2-12.5 cm), and the median tumor depth was 4.8 mm (range, 0.3-45.0 mm). One hundred ninety-one patients underwent SLN biopsy, and 59 (31%) were SLN-positive. Increasing primary tumor diameter and increasing tumor depth were associated with SLN positivity (P = .007 and P = .017, respectively). Age and sex were not associated with the SLN status. Immunosuppression, increasing tumor diameter, and increasing tumor depth were associated with worse OS (P = .007, P = .003, and P = .025, respectively). DSS differed significantly by group and was best for patients with a negative SLN and worst for those with primary MCC and synchronous clinically evident nodal disease (P = .018).

conclusionFor patients with MCC, increasing primary tumor diameter and increasing tumor depth are independently predictive of a positive SLN, worse OS, and worse DSS. Tumor depth should be routinely reported when primary MCC specimens are being evaluated histopathologically.

Indexed as

AgedCarcinoma, Merkel CellDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLymphatic MetastasisMaleProportional Hazards ModelsRetrospective StudiesSentinel Lymph Node BiopsySkin NeoplasmsMerkel cell carcinomasentinel lymph nodesurvivaltumor depthtumor diameter

Identifiers

PMID26038193
PMCPMC4904725

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.